Tech Company Financing Transactions

Xilio Therapeutics Funding Round

Xilio Therapeutics closed a $30 million Series A funding round on 9/28/2018. Investors included Atlas Venture, F-Prime Capital and private investors.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

828 Winter St.
Waltham, MA 02451
USA

Phone

Undisclosed

Website

www.xiliotx.com

Email Address

Not Recorded

Overview

Xilio is a Waltham, Massachusetts-based biopharmaceutical company focused on defeating cancer. The company's proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body -- a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Rene Russo

        

Chief Medical Officer

Marty Huber

        

Chief Operating Officer

Joseph Farmer

        

President

Timothy Clackson

        

VP - R & D

Ronan O'Hagan

        

Browse more venture capital transactions:

Prev: 9/28/2018: AbCellera venture capital transaction
Next: 9/28/2018: Broadly venture capital transaction

Share this article

About Database of VC Transactions

We do our best to report on tech company VC transactions. VC investment data records on this site are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary